Aspen Pharmacare says it is not yet able to confirm whether investigative research house Viceroy Research is compiling a report about the company.
This comes after its shares slid more than 10% on the JSE —
Viceroy, research responsible for publishing Steinhoff International’s expose, is rumored to be looking into the pharmaceutical company’s affairs. Viceroy is a company that identifies short-selling opportunities in financial markets.
Viceroy says, "Aspen shareholders are advised that it has had no contact with Viceroy Research and, as such, is unable to confirm that this speculation is correct,".
Aspen however, responded to the news saying it is not aware of "any information of a price-sensitive nature that requires communication to shareholders".
The company’s trading in the current financial year had been consistent with the prospects published in its 2017 financial year results statement in September.
Yesterday the company’s shares fell more than 10% at one stage to R234.98 on Tuesday. The company’s stock however picked-up again and rose by 1% at R258 at 3.19pm.
Steinhoff’s shares took yet another knock to 15.32% at R7.35 after it was revealed that the European Central Bank had sold its bond holdings in the company.